ENSC Ensysce Biosciences, Inc.

Nasdaq ensysce.com


$ 2.47 $ 0.00 (0 %)    

Wednesday, 15-Oct-2025 10:38:36 EDT
QQQ $ 606.04 $ 2.20 (0.36 %)
DIA $ 465.76 $ 1.12 (0.24 %)
SPY $ 668.91 $ 2.13 (0.32 %)
TLT $ 91.17 $ 0.21 (0.23 %)
GLD $ 386.24 $ 0.29 (0.08 %)
$ 2.47
$ 2.47
$ 2.44 x 409
$ 2.47 x 100
$ 2.46 - $ 2.49
$ 1.62 - $ 14.67
86,318
na
7.33M
$ 2.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-10-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-14-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 06-08-2021 03-31-2021 10-Q
19 03-15-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-10-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 03-11-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-01-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 03-09-2018 12-31-2017 10-K
32 01-09-2018 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ensysce-biosciences-showcases-taap-and-mpar-platforms-in-painweek2025-symposium-highlights-redefining-opioid-safety-amid-global-crisis

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company p...

 ensysce-biosciences-q2-eps-079-beats-118-estimate-sales-1371m-beat-650000k-estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $...

 watching-ensysce-biosciences-zacks-small-cap-research-reiterates-1845-price-valuation-was-originally-given-on-may-14-2025

https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07162025_ENSC_Sorensen.pdf

 ensysce-biosciences-launches-phase-3-trial-for-abuse-resistant-painkiller-pf614-selects-rho-inc-as-clinical-partner

~ FDA Protocol Review Completed ~~ Rho, Inc. Selected as Clinical Research Partner ~SAN DIEGO, CA / ACCESS Newswire / July 16, ...

 ensysce-biosciences-says-it-fully-enrolled-part-2-of-critical-three-part-pf614-mpar-102-clinical-study-to-study-effect-of-food-on-mpar-technology

~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~~ Grant Funds from NIDA Accelerating Clinical Developmen...

 ensysce-biosciences-secures-53m-in-continued-nida-support-to-advance-opioid-overdose-protection

~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~~ Funds Accelerate Path Towards Commercialization ~

 watching-ensysce-biosciences-zacks-small-cap-research-gives-stock-1845-price-valuation

https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_05142025_ENSC_Sorensen.pdf

 ensysce-biosciences-q1-eps-139-beats-302-estimate-sales-132m-up-from-30572k-yoy

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.39) per share which beat the analyst consensus estimate of $...

 ensysce-biosciences-stock-doubles-in-one-trading-session---heres-why

Ensysce Biosciences rises after patent notice for PF9001, a methadone prodrug aimed at safer opioid use with overdose protectio...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION